evaluation includes all activities relating to the processing of
marketing-authorization applications (MAA) for new medicines which have never
been assessed before. It covers from the pre-submission discussion with future
applicants, through evaluation by the CHMP, to the granting of a marketing
authorization by the European Commission.
trend is being observed over the last five years. In 2013, 80 applications for
medicinal products were received, while in 2016 it reached 114 applications.
increase has been detected in biosimilar products achieving in 2016 the highest
number of applications in a year so far with 14 new applications.
would like to highlight this record as we are currently working in many
biosimilar projects. We have large experience in biosimilar’s Scientific
Advice, dossier preparation, due diligence, RMP, publishing, assistance during
product development and many more services.
have experience in FDA biosimilar projects such as BLA, IND meeting and
If you have
a biosimilar project we can help you on regulatory requirements in EMA and FDA.
Contact us at firstname.lastname@example.org and get more information!